Natera
NTRA
$194.75
-2.71%
Natera, Inc. is a diagnostic and research company operating in the healthcare sector, specifically within medical diagnostics and research. It leverages proprietary molecular and bioinformatics technology to offer a suite of tests, including its flagship Panorama Non-Invasive Prenatal Test (NIPT), Horizon Carrier Screening, and the Signatera molecular residual disease (MRD) test for oncology. The company has established itself as a disruptive leader in cell-free DNA testing, particularly in reproductive health and oncology, with its Signatera test gaining significant traction as a tool for cancer recurrence monitoring. The current investor narrative is intensely focused on the company's path to sustainable profitability, following a landmark quarter of positive net income, and the scaling of its high-growth oncology segment, which is seen as the primary driver for its future valuation.…
NTRA
Natera
$194.75
Related headlines
Investment Opinion: Should I buy NTRA Today?
Rating & Thesis: Hold. Natera presents a compelling but high-risk growth story at a critical juncture; investors should wait for confirmation that Q4 profitability is sustainable before establishing new positions. The analyst sentiment, where available, is positive (e.g., Morgan Stanley Overweight), but the lack of a consensus price target underscores the uncertainty.
Supporting Evidence: The hold rating is supported by four key data points: 1) The strong Q4 revenue growth of 39.8% YoY demonstrates powerful underlying demand. 2) The positive net income of $47.26M and net margin of 7.1% in Q4 is a pivotal fundamental improvement. 3) The valuation, at 13.58x trailing sales, is rich but has compressed from historical extremes, potentially offering a more reasonable entry if growth persists. 4) The balance sheet is a major strength, with a debt-to-equity of 0.125 and $1.07B in cash, providing a significant margin of safety.
Risks & Conditions: The two biggest risks are a failure to maintain quarterly profitability and a deceleration in revenue growth below 30%. This Hold would upgrade to a Buy on a sustained break above the $230 resistance level coupled with a second consecutive quarter of positive net income. It would downgrade to a Sell if the stock breaks below the $182 support level on a closing basis or if QoQ revenue growth turns negative. The stock is currently fairly valued relative to its own recent history and growth profile, but remains overvalued on traditional profitability metrics.
Sign up to view all
NTRA 12-Month Price Forecast
The outlook for NTRA is balanced with near-term uncertainty. The fundamental story improved dramatically with the Q4 profit, but the stock's weak technicals and high volatility demand caution. The base case of range-bound consolidation is most probable as the market demands more evidence. The stance would upgrade to bullish on a confirmed second profitable quarter and a technical breakout above $230. It would turn bearish on a breakdown below $182, which would signal a failure of the recent consolidation and open the path to the 52-week low. The pristine balance sheet is a critical factor that limits catastrophic downside but does not preclude significant volatility.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Natera's 12-month outlook, with a consensus price target around $253.18 and implied upside of +30.0% versus the current price.
Average Target
$253.18
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$156 - $253
Analyst target range
Analyst coverage for Natera appears limited, with data showing only 5 analysts providing estimates for future EPS and revenue, but no consensus price target or recommendation breakdown is provided in the dataset. The institutional ratings data shows a series of reiterations from major firms in late 2025 and early 2026, with actions like 'Overweight' from Morgan Stanley and JP Morgan, 'Outperform' from Baird and Evercore ISI, and 'Equal Weight' from Wells Fargo. The most recent rating was an 'Overweight' reiteration by Morgan Stanley on March 3, 2026. The absence of a consensus price target and the small number of estimating analysts suggests that while the stock is covered by several major institutions, formal price target coverage may be sparse or not aggregated in this data. This can be common for growth companies with complex, evolving stories, leading to higher valuation uncertainty and price volatility as the market seeks to establish a firm valuation anchor based on evolving fundamentals.
Bulls vs Bears: NTRA Investment Factors
The investment debate for Natera centers on the sustainability of its Q4 2025 profitability inflection against a backdrop of technical weakness and premium valuation. Bullish evidence is currently stronger, anchored by the concrete, data-driven milestone of positive net income and exceptional 39.8% revenue growth, supported by a pristine balance sheet. However, the bear case is potent, highlighted by the stock's severe 3-month underperformance, high volatility (beta 1.68), and the fact that profitability on a trailing basis remains negative. The single most important tension is whether Q4's net income of $47.26 million marks the beginning of consistent, scalable profitability that can support its 13.58x sales multiple, or if it proves to be a one-time anomaly amidst ongoing cash burn from growth investments. The resolution of this tension in upcoming quarters will dictate the stock's direction.
Bullish
- Q4 Profitability Inflection: Natera delivered a landmark quarter of positive net income of $47.26 million in Q4 2025, representing a net margin of 7.1%. This is a dramatic swing from net losses in the prior three quarters and signals a potential sustainable shift towards profitability.
- Exceptional Revenue Growth: Revenue growth accelerated to 39.8% YoY in Q4 2025, reaching $665.5 million. This robust top-line expansion, driven by the high-growth oncology segment, demonstrates strong market demand and execution.
- Strong Balance Sheet & Cash Flow: The company boasts a fortress balance sheet with a strong current ratio of 3.39, minimal debt (D/E of 0.125), and over $1.07 billion in cash. Positive TTM free cash flow of $96.61 million and Q4 operating cash flow of $73.89 million provide ample internal funding for growth.
- High Gross Margin Stability: Gross margin remains robust at 67.14% for Q4 2025, consistent with the TTM gross margin of 64.85%. This indicates strong pricing power and cost control in its core testing business, providing a solid foundation for future operating leverage.
Bearish
- Technical Downtrend & High Volatility: The stock is in a pronounced downtrend, down 15.66% over 3 months and underperforming the SPY by 19.25 points. With a beta of 1.68, it is 68% more volatile than the market, indicating high risk and potential for further downside.
- Trailing Profitability Remains Negative: Despite the positive Q4, trailing twelve-month metrics show a net loss, with a negative net margin of -9.03% and negative trailing P/E of -150.5. The market requires consistent quarterly profits to validate the Q4 inflection.
- Elevated Valuation Multiples: The stock trades at a trailing PS ratio of 13.58x and an EV/Sales of 11.99x. While compressed from historical highs, these are still premium multiples that demand flawless execution and sustained high growth to justify.
- Lack of Clear Valuation Anchor: Analyst coverage is limited with only 5 analysts providing estimates, and no consensus price target is available. This creates higher valuation uncertainty and can exacerbate price swings as the market searches for a firm anchor.
NTRA Technical Analysis
The stock is in a pronounced downtrend from its recent highs, trading down 15.66% over the past three months and 10.96% year-to-date as of April 24, 2026, despite a strong 31.89% gain over the past year. With a current price of $203.75, it sits approximately 20.5% below its 52-week high of $256.36 and 54.6% above its 52-week low of $131.81, positioning it in the lower-middle of its annual range, suggesting the momentum from the prior year's rally has decisively broken. Recent momentum is weak and divergent from the longer-term trend; the stock is up a modest 3.23% over the past month but has significantly underperformed the SPY, which gained 8.7% over the same period, resulting in a negative relative strength of -5.47 points. This 1-month uptick against a backdrop of a sharp 3-month decline suggests a potential consolidation or dead-cat bounce rather than a convincing reversal, especially given the high beta of 1.68, which indicates the stock is 68% more volatile than the broader market. Key technical support is anchored at the 52-week low of $131.81, while immediate resistance is at the recent breakdown level near $230 and the 52-week high of $256.36. A sustained break below the $182 level (recent March low) could signal a retest of deeper support, whereas reclaiming the $230-$240 zone would be necessary to invalidate the current bearish structure. The elevated beta of 1.68 underscores the stock's high-risk, high-reward profile, demanding careful position sizing given its propensity for outsized swings.
Beta
1.68
1.68x market volatility
Max Drawdown
-28.2%
Largest decline past year
52-Week Range
$132-$256
Price range past year
Annual Return
+25.7%
Cumulative gain past year
| Period | NTRA Return | S&P 500 |
|---|---|---|
| 1m | +4.2% | +12.6% |
| 3m | -15.9% | +2.5% |
| 6m | -2.1% | +4.3% |
| 1y | +25.7% | +28.4% |
| ytd | -14.9% | +4.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NTRA Fundamental Analysis
Natera's revenue trajectory is exceptionally strong, with Q4 2025 revenue reaching $665.5 million, representing a 39.8% year-over-year growth rate. This acceleration is evident from the sequential quarterly increases from $501.83 million in Q1 to $665.5 million in Q4, driven overwhelmingly by its Product segment, which contributed $661.16 million of the total, while Licensing and other revenue was a minimal $4.34 million. The company achieved a critical inflection point in profitability during Q4 2025, reporting net income of $47.26 million and a net margin of 7.1%, a dramatic swing from net losses in the preceding three quarters of -$66.94M, -$100.94M, and -$87.54M. Gross margin remains robust at 67.14% for the quarter, consistent with the trailing gross margin of 64.85%, indicating strong pricing power and cost control in its core testing business. The balance sheet and cash flow position are solid, with a strong current ratio of 3.39, a very low debt-to-equity ratio of 0.125, and positive free cash flow of $96.61 million on a TTM basis. The company generated $73.89 million in operating cash flow in Q4 alone, and with over $1.07 billion in cash, it possesses ample liquidity to fund its growth initiatives internally without reliance on dilutive financing, significantly de-risking the investment case.
Quarterly Revenue
$665500000.0B
2025-12
Revenue YoY Growth
+0.39%
YoY Comparison
Gross Margin
+0.67%
Latest Quarter
Free Cash Flow
$96613000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NTRA Overvalued?
Given the company's recent quarterly net income was positive but its trailing twelve-month metrics still show a net loss, we lead with the Price-to-Sales (PS) ratio, which is more reflective of its high-growth, pre-sustained-profitability phase. Natera trades at a trailing PS ratio of 13.58x and an EV/Sales of 11.99x. Compared to industry averages (data not available in the provided set), we cannot quantify a sector premium/discount, but these multiples are typical for a high-growth diagnostic company with >30% revenue growth. The valuation implies the market is pricing in continued rapid top-line expansion and a successful transition to consistent profitability. Historically, Natera's own PS ratio has compressed significantly from extreme levels above 50x in 2021 to the current 13.58x, which is near the lower end of its multi-year historical range. For context, its PS ratio was 47.06x as recently as Q4 2025, but that calculation used a different share count and price. The current multiple suggests the market has moved from valuing Natera on pure hyper-growth potential to a more measured growth-plus-path-to-profitability model, potentially offering a more reasonable entry point if execution continues.
PE
-150.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -124x~166x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-115.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is the company's reliance on continued hyper-growth to justify its premium valuation of 13.58x sales, as trailing profitability metrics remain negative with a net margin of -9.03%. While Q4 showed a positive inflection, a reversion to net losses in subsequent quarters would severely damage investor confidence. Revenue, while diversified across tests, is heavily concentrated in the Product segment ($661.16M of $665.5M in Q4), creating exposure to any slowdown in test volume or pricing pressure in its core markets of prenatal and oncology diagnostics.
Market & Competitive Risks: The stock faces significant valuation compression risk; its current PS ratio of 13.58x, while lower than historical peaks, remains elevated and is vulnerable to multiple contraction if growth decelerates or if the broader market de-rates high-growth, unprofitable healthcare stocks. Its high beta of 1.68 means it is highly sensitive to market downturns and sector rotation out of growth. Competitive risks are inherent in the rapidly evolving molecular diagnostics space, where technological disruption and payer reimbursement changes could threaten its flagship Panorama and Signatera tests.
Worst-Case Scenario: The worst-case scenario involves a combination of a growth scare (e.g., QoQ revenue decline), a return to significant quarterly net losses, and a broad market sell-off that disproportionately hits high-beta stocks. This could trigger a rapid de-rating, sending the stock to retest its 52-week low of $131.81. From the current price of $203.75, this represents a realistic downside of approximately -35%. A break below the recent March low of $182.65 would likely be the technical trigger for such a move, potentially exacerbated by high short interest (short ratio of 3.91).
FAQ
The key risks are: 1) Profitability Risk: The company must prove its Q4 2025 net income of $47.26M is repeatable; a return to losses would crush sentiment. 2) Valuation & Volatility Risk: The high PS ratio of 13.58x and beta of 1.68 make the stock prone to severe swings in a risk-off market. 3) Execution Risk: Revenue growth must remain above 30% to justify its multiple; any slowdown would trigger a de-rating. 4) Competitive/Regulatory Risk: The molecular diagnostics space is competitive, and changes in insurance reimbursement could impact pricing and volumes.
The 12-month forecast is bifurcated, with a 50% probability base case target range of $200-$240, implying the stock consolidates near current levels. The bullish case (30% probability) targets $256-$280, requiring sustained profitability and growth acceleration. The bearish case (20% probability) targets $132-$182, triggered by a return to losses and growth deceleration. The most likely scenario is the base case, where the company shows progress but the stock remains volatile as the market demands more proof. The lack of a firm analyst consensus price target adds to the forecast uncertainty.
NTRA's valuation is rich and context-dependent. On a trailing Price-to-Sales basis at 13.58x, it carries a significant growth premium, typical for a company growing revenue at nearly 40%. It is not cheap by any traditional metric, as it still shows a trailing net loss. However, compared to its own historical multiples which were above 50x, the current multiple represents a material compression. The stock is fairly valued relative to its own recent history and growth profile but would be considered overvalued if growth decelerates or profitability proves inconsistent. The market is pricing in a successful transition to consistent, scalable profits.
NTRA is a high-risk, high-potential-reward stock that may be a good buy for aggressive growth investors, but not for the risk-averse. The Q4 2025 profit inflection and 39.8% revenue growth are powerful bullish signals, and the strong balance sheet limits bankruptcy risk. However, the stock's high volatility (beta 1.68), recent 15.66% 3-month decline, and premium valuation of 13.58x sales mean it is not a stable investment. It could be a good buy on a pullback towards the $180-$190 support zone for investors who believe the profitability trend will continue.
NTRA is primarily suitable for a long-term investment horizon of 3-5 years, not short-term trading. Its value will be determined by the multi-year scaling of its Signatera oncology platform and the sustainability of its profitability transition, which are not quarter-to-quarter stories. However, its high beta of 1.68 and technical volatility offer opportunities for tactical traders, but this requires significant risk management. Long-term investors can better weather the inevitable volatility while capturing the potential upside if the company's disruptive technology gains widespread adoption. A minimum holding period of 18-24 months is suggested to allow the fundamental thesis to play out.